3//SEC Filing
Athyrium Opportunities Fund (A) LP 3
Accession 0000899243-20-017174
CIK 0001580063other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 8:40 PM ET
Size
27.9 KB
Accession
0000899243-20-017174
Insider Transaction Report
Form 3
PROGENITY, INC.PROG
Athyrium Opportunities Fund (A) LP
10% Owner
Holdings
- (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying)
Athyrium Opportunities 2020 LP
10% Owner
Holdings
- (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying)
Holdings
- (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying) - (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying)
Holdings
- (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying) - (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying)
Holdings
- (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying) - (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying)
Holdings
- (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying) - (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying)
Holdings
- (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying) - (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying)
Athyrium Opportunities Fund (B) LP
10% Owner
Holdings
- (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying) - (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying)
Holdings
- (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying) - (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying)
Athyrium Opportunities Associates LP
10% Owner
Holdings
- (indirect: See footnotes)
Unsecured Convertible Promissory Note
→ Common Stock (1,079,097 underlying) - (indirect: See footnotes)
Series B Preferred Stock Purchase Warrant
Exp: 2022-10-27→ Common Stock (359,699 underlying) - (indirect: See footnotes)
Series B Preferred Stock
→ Common Stock (16,467,504 underlying)
Footnotes (9)
- [F1]The Unsecured Convertible Promissory Note (the "Convertible Note") has a maturity date of May 8, 2022 and is convertible at the option of the holder into shares of Series B Preferred Stock with an initial conversion price of $2.25 per share (subject to certain anti-dilution adjustments), but will automatically be converted into shares of the Issuer's common stock in connection with the Issuer's initial public offering. The number of shares of common stock issuable upon such conversion is calculated by dividing (i) the outstanding principal amount of the Convertible Note by (ii) the lesser of (A) the conversion price then in effect and (B) the product of (I) the price specified in the final prospectus with respect to the public offering and (II) eighty percent (80%).
- [F2]The Convertible Note is owned directly by Athyrium Opportunities 2020 LP. Athyrium Opportunities Associates III GP LLC is the general partner of Athyrium Opportunities Associates III LP, which is the general partner of Athyrium Opportunities 2020 LP. Athyrium Funds GP Holdings, LLC is the managing member of Athyrium Opportunities Associates III GP LLC. Jeffrey Ferrell is the managing member of Athyrium Funds GP Holdings, LLC and President of Athyrium Opportunities Associates III GP LLC.
- [F3]Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein.
- [F4]The Series B Preferred Stock (the "Series B Preferred Stock") is convertible into shares of common stock of the Issuer at any time at the option of the holders thereof and has no stated maturity or expiration date. The Series B Preferred Stock will automatically be converted into shares of the Issuer's common Stock upon the completion of the Issuer's initial public offering at a conversion rate of 6.178 shares of common stock per share of Series B Preferred Stock, with such conversion rate subject to certain anti-dilution adjustments.
- [F5]The shares of Series B Preferred Stock are owned directly by Athyrium Opportunities Fund (A) LP, Athyrium Opportunities Fund (B) LP, Athyrium Opportunities III Acquisition 2 LP and Athyrium Opportunities III Co-Invest 1 LP in an amount exercisable in 3,786,098, 2,093,586, 6,834,284 and 3,753,536 shares of common stock, respectively. Athyrium Opportunities Associates III GP LLC is the general partner of Athyrium Opportunities Associates III LP, which is the general partner of Athyrium Opportunities III Acquisition 2 LP. Athyrium Opportunities Associates Co-Invest LLC is the general partner of Athyrium Opportunities III Co-Invest 1 LP. Athyrium Opportunities Associates GP LLC is the general partner of Athyrium Opportunities Associates LP, which is the general partner of each of Athyrium Opportunities Fund (A) LP and Athyrium Opportunities Fund (B) LP. Athyrium Opportunities Advisers LLC is the investment adviser of each of Athyrium Opportunities Fund (A) LP
- [F6](Continue from Footnote 5) and Athyrium Opportunities Fund (B) LP. Athyrium Capital Management, LP is a member of Athyrium Opportunities Associates GP LLC and an investment sub-adviser of Athyrium Opportunities Advisers LLC. NB Alternatives GP Holdings LLC is also a member of Athyrium Opportunities Associates GP LLC. NB Alternatives Holdings LLC is the sole member of NB Alternatives GP Holdings LLC and is a member of NB Alternatives Advisers LLC. NB Alternatives Advisers LLC is the sole member of Athyrium Opportunities Advisers LLC. Athyrium Funds GP Holdings, LLC is the managing member of Athyrium Opportunities Associates Co-Invest LLC and Athyrium Opportunities Associates III GP LLC. Athyrium Capital Holdings, LLC is the general partner of Athyrium Capital Management, LP.
- [F7](Continue from Footnote 6) Jeffrey A. Ferrell is the managing member of Athyrium Capital Holdings, LLC and Athyrium Funds GP Holdings, LLC and the President of Athyrium Capital Management, LP, Athyrium Opportunities Associates Co-Invest LLC, Athyrium Opportunities Associates III GP LLC, and Athyrium Opportunities Associates GP LLC.
- [F8]The Series B Preferred Stock Purchase Warrant (the "Warrant") is exercisable for Series B Preferred Stock at an exercise price of $2.25 per share (subject to certain anti-dilution adjustments) at any time at the option of the holders thereof or at its scheduled maturity on October 27, 2022. Upon the completion of the Issuer's initial public offering, the Warrant will automatically become exercisable for a number shares of common stock equal to the number of shares of common stock that would be issuable upon conversion of the shares of Series B Preferred Stock subject to purchase pursuant to the Warrant as of the date of consummation of such initial public offering.
- [F9]The Warrant is owned directly by Athyrium Opportunities III Co-Invest 1 LP. Athyrium Opportunities Associates Co-Invest LLC is the general partner of Athyrium Opportunities III Co-Invest 1 LP. Athyrium Funds GP Holdings, LLC is the managing member of Athyrium Opportunities Associates Co-Invest LLC. Jeffrey A. Ferrell is the managing member of Athyrium Funds GP Holdings, LLC.
Documents
Issuer
PROGENITY, INC.
CIK 0001580063
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001589714
Filing Metadata
- Form type
- 3
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 8:40 PM ET
- Size
- 27.9 KB